Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Alcazer

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Blood|June 4, 2026
Shrouded in a starry sky: a case of AML-MRC with KMT2A amplification mimicking Burkitt-like morphologyRadu Chiriac, Vincent Alcazer
Bulletin Du Cancer|December 18, 2021
[Development of allogeneic CAR T-cells]Vincent Alcazer, Stéphane Depil
Bulletin Du Cancer|June 5, 2024
[Momelotinib as first-line or second-line treatment following ruxolitinib in patients with primary or secondary myelofibrosis]Axel Sudria, Vincent Alcazer
The Journal of Molecular Diagnostics : JMD|April 15, 2022
Panel Informativity Optimizer: An R Package to Improve Cancer Next-Generation Sequencing Panel InformativityVincent Alcazer, Pierre Sujobert
Oncotarget|July 2, 2019
Cancer vaccines: what's next?Stéphane Depil, Paola Bonaventura, Vincent Alcazer
Cancers|March 12, 2020
Human Endogenous Retroviruses (HERVs): Shaping the Innate Immune Response in CancersVincent Alcazer, Paola Bonaventura, Stephane Depil
American Journal of Hematology|October 10, 2024
Endogenous retroelements in hematological malignancies: From epigenetic dysregulation to therapeutic targetingMohamed Chour, Françoise Porteu, Stéphane Depil, et al.
Bulletin Du Cancer|January 29, 2019
Vincent Alcazer, Christophe Delenda, Laurent Poirot, et al.
Expert Review of Vaccines|March 22, 2018
Vaccination post-allogeneic hematopoietic stem cell transplantation: what is feasible?Anne Conrad, Vincent Alcazer, Florent Valour, et al.
Ejhaem|January 27, 2025
What is the origin of the normal ranges of blood cell counts? An evolutionary perspectiveManon Zala, Vincent Alcazer, Laetitia Largeaud, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Blood|June 4, 2026
Shrouded in a starry sky: a case of AML-MRC with KMT2A amplification mimicking Burkitt-like morphologyRadu Chiriac, Vincent Alcazer
Bulletin Du Cancer|December 18, 2021
[Development of allogeneic CAR T-cells]Vincent Alcazer, Stéphane Depil
Bulletin Du Cancer|June 5, 2024
[Momelotinib as first-line or second-line treatment following ruxolitinib in patients with primary or secondary myelofibrosis]Axel Sudria, Vincent Alcazer
The Journal of Molecular Diagnostics : JMD|April 15, 2022
Panel Informativity Optimizer: An R Package to Improve Cancer Next-Generation Sequencing Panel InformativityVincent Alcazer, Pierre Sujobert
Oncotarget|July 2, 2019
Cancer vaccines: what's next?Stéphane Depil, Paola Bonaventura, Vincent Alcazer
Cancers|March 12, 2020
Human Endogenous Retroviruses (HERVs): Shaping the Innate Immune Response in CancersVincent Alcazer, Paola Bonaventura, Stephane Depil
American Journal of Hematology|October 10, 2024
Endogenous retroelements in hematological malignancies: From epigenetic dysregulation to therapeutic targetingMohamed Chour, Françoise Porteu, Stéphane Depil, et al.
Bulletin Du Cancer|January 29, 2019
Vincent Alcazer, Christophe Delenda, Laurent Poirot, et al.
Expert Review of Vaccines|March 22, 2018
Vaccination post-allogeneic hematopoietic stem cell transplantation: what is feasible?Anne Conrad, Vincent Alcazer, Florent Valour, et al.
Ejhaem|January 27, 2025
What is the origin of the normal ranges of blood cell counts? An evolutionary perspectiveManon Zala, Vincent Alcazer, Laetitia Largeaud, et al.
Pageof 5